Flamm – Advisory Committees or Review Panels: Gilead, Bristol Myers Squibb, AbbVie, Janssen, Salix; Consulting: Merck, Janseen, Bristol Myers Squibb, AbbVie, Salix, Gilead; Grant/Research Support: Janssen, Bristol Myers Squibb, Merck, Vertex, Gilead, AbbVie, Boehringer Ingelheim; Speaking and Teaching: Salix Jill M. Denning – Employment: Gilead Sciences, Inc. Sarah Arterburn – Employment: Gilead Sciences Inc.; Stock Shareholder: selleck chemical Gilead Sciences Inc. Phillip S. Pang – Employment: Gilead Sciences John G. McHutchison

– Employment: Gilead Sciences; Stock Shareholder: Gilead Sciences Michael P. Curry – Grant/Research Support: Gilead Sciences, Mass Biologics, Merck, Salix, Conatus; Stock Shareholder: Achilion, Idenix The following people have nothing to CB-839 mw disclose: Theo Brandt-Sarif, Michael Charl-ton Background: The all-oral antiviral regimen using sofosbuvir (SOF) and simeprevir (SMV) with/without ribavirin (RBV) has been reported to lead to high sustained virologic response (SVR) rates along with minimal adverse events (AE) when treating patients with hepatitis C genotype 1 (HCV GT1). The efficacy of this regimen in liver transplant (LT) recipients has not been described to date. Objective: To report the virological response, safety, and tolerability of SOF+SMV with/ without RBV in treating LT recipients with HCV GT1 for

12 weeks. Results: To date, 77 patients met criteria to consider treatment and 55 patients (78% male, 29% non-white, 73% subtype 1a, 77% IL28B CT/TT, 87% HCV RNA >800,000 IU/mL, 24% F3-4 with 4% decompensation and 15% choles-tatic recurrence, 7% DNA ligase status post kidney transplantation) have received SOF+SMV, being followed for a median of 11 weeks (range 1-23 weeks). 83% previously failed or did not tolerate peginterferon+RBV (PR)-based treatments (68% with PR, 13% with PR+telaprevir/boceprevir, and 2% with PR+SOF). Weight-based RBV was used in 14 patients (25%) at the discretion of the treating physicians. RBV dose reduction and/or erythro-poietin

administration was required in 64% of these patients. Median time from LT to treatment was 22 months (range 2-272 months). Tacrolimus was the primary immunosuppression (IS) in 86% of patients, the remainder were on cyclosporine. Minimal IS dose adjustments were required during treatment. 4 patients (7%) had estimated GFR <30 mL/min. On-treatment virolog-ical response rates are shown in the Table. Of 40 patients who received treatment ≥4 weeks, 39 patients achieved HCV RNA